BioCentury製作的BioCentury This Week
BioCentury
分类: 科學與醫學
加到我的清單
听听最后一集:
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the proposal, as well as a concession for the biopharma industry on first-in-human studies in PDUFA reauthorization negotiations with FDA. The analysts also discuss the latest pair of billion-dollar biotech deals: Gilead's $3.2 billion takeout of a...
以前的剧集
-
370 - Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds Mon, 13 Apr 2026
-
369 - Ep. 359 - 2Q markets preview, tariffs and biotech takeouts Mon, 06 Apr 2026
-
368 - Ep. 358 - Europe's biotech challenge Wed, 01 Apr 2026
-
367 - Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision Mon, 30 Mar 2026
-
366 - Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN Mon, 23 Mar 2026
-
365 - Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline Mon, 16 Mar 2026
-
364 - Ep. 354 - East-West Summit Takeaways Fri, 13 Mar 2026
-
363 - Ep. 353 - Prasad Departure and Future of Fibrosis Therapies Mon, 09 Mar 2026
-
362 - Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight Mon, 02 Mar 2026
-
361 - Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint Mon, 23 Feb 2026
-
360 - Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA Tue, 17 Feb 2026
-
359 - Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch Mon, 09 Feb 2026
-
358 - Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules Mon, 02 Feb 2026
-
357 - Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos Mon, 26 Jan 2026
-
356 - Ep. 346 - 2026 Public Markets Preview Thu, 22 Jan 2026
-
355 - Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN Tue, 20 Jan 2026
-
354 - Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation Thu, 15 Jan 2026
-
353 - Ep. 343 - JPM Deals, Policy Outlook, Approval Trends Mon, 12 Jan 2026
-
352 - Ep. 342 - 2026 Biotech Kickoff Mon, 05 Jan 2026
-
351 - Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI Mon, 29 Dec 2025
-
350 - Ep. 340 - Obesity Data, Kymera & FDA Survey Results Mon, 15 Dec 2025
-
349 - Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult Mon, 08 Dec 2025
-
348 - Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding Mon, 01 Dec 2025
-
347 - Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc Mon, 24 Nov 2025
-
346 - Ep. 336 - Cautious Optimism and M&A Momentum Fri, 21 Nov 2025
-
345 - Ep. 335 - Neurology's Coming Inflection Point Thu, 20 Nov 2025
-
344 - Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi Mon, 17 Nov 2025
-
343 - Ep. 333 - Is This Korea’s Biotech Moment? Wed, 12 Nov 2025
-
342 - Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA Mon, 10 Nov 2025
-
341 - Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster Mon, 03 Nov 2025
-
340 - Ep. 330 - China's Innovation Moment Fri, 31 Oct 2025
-
339 - Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors Mon, 27 Oct 2025
-
338 - Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers Mon, 20 Oct 2025
-
337 - Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg Wed, 15 Oct 2025
-
336 - Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A Mon, 13 Oct 2025
-
335 - Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund Mon, 06 Oct 2025
-
334 - Ep. 324 - Genmab, GSK and Drug Pricing Mon, 29 Sep 2025
-
333 - Ep. 323 - Agentic AI: From New Targets to the Clinic Wed, 24 Sep 2025
-
332 - Ep. 322 - Takeaways from BioCentury Grand Rounds Europe Tue, 23 Sep 2025
-
331 - Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus Mon, 22 Sep 2025
-
330 - Ep. 320 - U.K. Biotech, U.S.-China, Insmed Mon, 15 Sep 2025
-
329 - Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more Mon, 08 Sep 2025
-
328 - Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines Tue, 02 Sep 2025
-
327 - Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat Mon, 25 Aug 2025
-
326 - Ep. 316 - Trends in Pharma Deals Mon, 18 Aug 2025
-
325 - Ep. 315 - China Speed: Data, Deals, First in Class Wed, 13 Aug 2025
-
324 - Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure Mon, 11 Aug 2025
-
323 - Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer Mon, 04 Aug 2025
-
322 - Ep. 312 - Biotech Progress Report Tue, 29 Jul 2025
-
321 - Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More Mon, 28 Jul 2025
显示更多剧集
5